ArticleOncology and therapy2026

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.

Daniel A Ermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.